Andrew Ross, MD
Gastroenterology · Seattle, WANPI 1063575587
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 80.9% of it on its own, with 6 other manufacturers making up the rest. Among gastroenterology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $890.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$80K
- Olympus Corporation$16K
- Olympus Corporation Of The Americas$2K
- Cook Medical LLC$471
- Olympus America Inc.$220
- Abbott$188
- plus $23 from 1 others
Across 39 payments — averaging $15,090 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$589K
What the payments were for
- Consulting fees$40,82341%
- Speaking & faculty fees$40,40041%
- Travel & lodging$13,19813%
- Food & beverage$4,3784%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 84 | $79,944 |
| Olympus Corporation | 8 | $15,603 |
| Olympus Corporation Of The Americas | 9 | $2,350 |
| Cook Medical LLC | 5 | $471 |
| Olympus America Inc. | 3 | $220 |
| Abbott | 1 | $188 |
| Bristol Myers Squibb | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$40,755
- EXALT Model D$18,575
- SPYBITE$8,510
- EXALT$5,804
- EVIS EXERA III COLONOVIDEOSCOPE$2,255
- SPYGLASS$1,990
- GENERAL ENDOCHOICE$1,037
- GENERAL HEMOSTASIS$500
- GENERAL - BILIARY DEVICES$331
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$188
- AXIOS$167
- Cook Medical Hemostasis$143
- APOLLO ESG System$130
- ORISE$123
- EXALT MODEL D CONTROLLER$123
- Cook Medical Metal Stents$116
- SPYSCOPE$113
- Hemospray$105
- ACCOLADE SR$103
How this compares
$98,798 in reported general payments places this provider in the 95th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 22 | $374 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 14 | $196 |
| Omeprazole | 12 | $165 |
| Famotidine | 24 | $149 |
| Ondansetron Hcl | 35 | $53 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Seattle
- Kris KowdleySeattle$1.4M
- Scott LeeSeattle$220K
- Alyssa ChoiSeattle$102K
- Shayan IraniSeattle$57K
- Laurens JanssensSeattle$56K
- George McDonaldSeattle$53K
- Adam TempletonSeattle$49K
- Sravanthi ParasaSeattle$47K
- Liam HilsonSeattle$37K
- Rotonya CarrSeattle$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.